ADC Therapeutics (ADCT) Operating Leases (2019 - 2026)

ADC Therapeutics has disclosed Operating Leases across 8 years of filings, most recently posting $946000.0 for Q2 2026.

• In Q2 2026, Operating Leases fell 68.98% year-over-year to $946000.0; the TTM figure through Jun 2026 stood at $946000.0 (down 68.98% YoY), while the FY2025 annual figure was $1.0 million, down 87.07% from the prior year.
• Operating Leases came in at $946000.0 for Q2 2026 at ADC Therapeutics, down from $991000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $12.4 million in Q1 2023 to a low of $946000.0 in Q2 2026.
• Average Operating Leases over 5 years is $7.0 million, with a median of $7.8 million recorded in 2022.
• Year-over-year, Operating Leases surged 79.65% in 2023 and tumbled 87.47% in 2026.
• Over 5 years, Operating Leases stood at $6.6 million in 2022, then soared by 55.09% to $10.2 million in 2023, then slipped by 21.46% to $8.0 million in 2024, then plunged by 87.07% to $1.0 million in 2025, then retreated by 8.51% to $946000.0 in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $946000.0 in Q2 2026, $991000.0 in Q1 2026, and $1.0 million in Q4 2025.